Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology ConferenceBusiness Wire • 02/22/24
Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer's Disease and Coya's Pathway to a “Pipeline in a Product”Business Wire • 02/21/24
Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory DiseasesBusiness Wire • 02/13/24
Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology ConferenceBusiness Wire • 01/29/24
Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call SeriesBusiness Wire • 01/18/24
Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson's Disease in Addition to Amyotrophic Lateral SclerosisBusiness Wire • 01/16/24
Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)Business Wire • 01/05/24
Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.Business Wire • 12/20/23
Coya Therapeutics, Inc. and Dr. Reddy's Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)Business Wire • 12/06/23
Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial ResultsBusiness Wire • 11/08/23
Coya Announces Acceptance of Oral Presentation, “Regulatory T Cell Expansion Strategy to Target Inflammation in Alzheimer's Disease: A Phase 1 Feasibility Study,” at the 18th International Conference on Alzheimer's and Parkinson's Disease in LisbonBusiness Wire • 10/27/23
Coya Therapeutics (Coya) Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's Disease (AD)Business Wire • 10/09/23
Coya Therapeutics Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium MeetingBusiness Wire • 10/05/23
Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium MeetingBusiness Wire • 10/03/23
Coya Therapeutics Licenses Exclusive Worldwide rights to Exosome Engineering Technology (EET) from Carnegie Mellon University (CMU)Business Wire • 09/22/23
Coya Therapeutics Successfully Engineers Regulatory T Cell (Treg) Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple DiseasesBusiness Wire • 09/07/23
Coya Therapeutics Announces Publication of Potential Novel Blood Biomarker Data in Amyotrophic Lateral Sclerosis (ALS) Patients That Accurately Reflect Therapeutic Responses When Treated with Regulatory T Cell (Treg) Enhancing TherapiesBusiness Wire • 08/31/23
Coya Therapeutics To Present Novel Proof of Concept Exosome Modification Technology at the 5th Exosome Based Therapeutic Development Summit in Boston, MA on September 7, 2023Business Wire • 08/25/23
Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, Joins Coya's Board of DirectorsBusiness Wire • 08/21/23